ARTICLE SUMMARY:
Built on the efforts of innovative start-ups, interventional cardiology has matured to become the province of large strategics. Elixir Medical is looking to challenge that hierarchy by helping lead the conversion from metal stents to bioresorbable scaffolds, and in the process build what the industry hasn’t seen in a while: a significant new cardiology company.
Innovation in interventional cardiology has changed significantly over the past few years, reflecting the changes taking place throughout the industry. The impact on cardiology is noteworthy because the specialty has, over the course of its nearly 40-year history, served as the model that device innovation has followed in the industry as a whole.
